Abstract:

In order to explore the effect of casein glycomacropeptide (CGMP) on xazolone-induced ulcerative colitis in mice, the control group was fed regular diet, while the model group and three treatment groups were administered CGMP at three doses of 5, 50 mg/(kg bw·d) and 500 mg/(kg bw·d) by oral gavage for 5 days after oxazolone challenge. The change of body weight was daily recorded and diamine oxidase (DAO) activity in serum, myeloperoxidase (MPO) activity, malonaldehyde (MDA) content in colon, and histological change of colon were determined after the last administration. Treatments with the three doses of CGMP showed improvement on oxazolone-induced ulcerative colitis, while the dose of 50 mg/(kg bw·d) CGMP seemed to be better. In conclusion, CGMP holds promising potential to be applied in a nutritional therapy for the treatment of ulcerative colitis.

Key words: casein glycomacropeptide, CGMP, oxazolone, ulcerative colitis